Neopterin Counters Vascular Inflammation and Atherosclerosis

Area of Science:

• Cardiovascular Research
• Immunology
• Biochemistry

Background:

• Neopterin, a GTP metabolite, is produced by activated macrophages.
• It is highly expressed in atherosclerotic lesions of human aorta, carotid, and coronary arteries.
• The precise role of neopterin in vascular inflammation and atherosclerosis requires further elucidation.

Purpose of the Study:

• To investigate the influence of neopterin on vascular inflammation and atherosclerosis.
• To assess the atheroprotective potential of neopterin in vitro and in vivo.

Main Methods:

• Examined neopterin expression in coronary artery lesions and plasma of patients with coronary artery disease.
• Evaluated neopterin's effects on human aortic endothelial cells, macrophages, and smooth muscle cells in vitro.
• Conducted in vivo studies using apolipoprotein E-deficient mice to assess neopterin's impact on aortic atherosclerotic lesions.

Main Results:

• Neopterin levels were significantly elevated in coronary artery lesions and plasma of patients with coronary artery disease.
• In vitro, neopterin reduced endothelial cell proliferation and inflammatory marker expression, attenuated monocyte adhesion, and suppressed macrophage foam cell formation.
• Neopterin inhibited smooth muscle cell migration and proliferation without inducing apoptosis.
• In vivo, exogenous neopterin administration retarded, while antibody-mediated neutralization promoted, atherosclerotic lesion development in mice.

Conclusions:

• Neopterin demonstrates significant atheroprotective properties by mitigating vascular inflammation and atherosclerosis.
• Neopterin may be endogenously induced to counteract atherosclerotic lesion progression.
• Neopterin represents a promising novel therapeutic target for atherosclerotic cardiovascular diseases.